Company / Current Liabilities
Gilead Sciences Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$11.8B
FY2025
5-year range
$11.2B / $12.0B
FY2021-FY2025
Trend
-1.6%
vs FY2024
Sector context
#9 of 213
Health Care
What the data says
Among 213 Health Care companies, Gilead Sciences is in the bottom 4% for current liabilities. Current Liabilities has fluctuated over the past 10 years, ranging from $9.2B in FY2016 to $12.0B in FY2024.
Based on SEC 10-K filings.
$11.8B in FY2025 with a 5-year CAGR of +0.7%. Top quartile in the Health Care sector.
Increased from $11.3B to $11.8B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +1.7%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 213This company $11.8B Sector average $1.6B
▼
+643.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +0.7%, indicating consistent growth.
- In FY2025, current liabilities decreased 1.6% year-over-year.
- Ranks #9 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8B | -1.6% |
| FY2024 | $12.0B | +6.4% |
| FY2023 | $11.3B | +0.4% |
| FY2022 | $11.2B | -3.2% |
| FY2021 | $11.6B | +1.9% |
| FY2020 | $11.4B | +16.8% |
| FY2019 | $9.8B | -8.0% |
| FY2018 | $10.6B | -8.9% |
| FY2017 | $11.6B | +26.2% |
| FY2016 | $9.2B | -6.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026